Breast cancer liver metastasis
Conditions
Interventions
experimental group:DEBTACE+ endocrine therapy
control group:endocrine therapy
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. According to the "Guidelines and Standards for the Diagnosis and Treatment of Breast Cancer of the Chinese Anti-Cancer Association (2019 Edition)", a clear diagnosis of luminal breast cancer with liver metastasis. 3. Pathologically confirmed HER2-negative breast cancer. 4. ECOG (Eastern Cooperative Oncology Group of the United States) physical status score 0-1 points. 5. Liver function Child-Pugh grade A or better grade B (<= 7 points) 6. The liver has at least one measurable target lesion required by RECIST 1.1; 7. The expected survival time is greater than 3 months; 8. The patient voluntarily joined the study and signed an informed consent form (ICF); 9. Those who are expected to have good compliance can follow up the efficacy and adverse reactions as required by the plan.
Exclusion criteria
Exclusion criteria: 1. Triple negative breast cancer; 2. There is severe liver and kidney dysfunction; 3. There are obvious contraindications for interventional therapy: those with obvious arteriovenous fistula; uncorrectable coagulation dysfunction and obvious abnormal blood picture, and those with obvious bleeding tendency; intractable large amounts of ascites; 4. Combined with active infection, especially inflammation of the biliary system; 5. Female patients during pregnancy and lactation, female patients with fertility and a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures during the entire test period; 6. According to the judgment of the investigator, there are accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study (including but not limited to severe hypertension that cannot be controlled by drugs, severe diabetes, etc.); 7. The researcher believes that the patient is not suitable to participate in any other situations in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactLiu Jibing
Shandong Cancer Hospital
Outcome results
None listed